Experimental drug talquetamab takes aim at stubborn myasthenia gravis

NCT ID NCT07499323

Not yet recruiting Disease control Sponsor: First Affiliated Hospital of Chongqing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This very early study will test the drug talquetamab in just 2 people with refractory generalized myasthenia gravis, a chronic autoimmune disease that causes muscle weakness. The drug is designed to help the immune system attack the cells that produce harmful antibodies. The goal is to see if it can improve daily living activities and reduce muscle weakness, while monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Talquetamab (a drug given as a shot under the skin)
What this could lead to: If it works, this could point toward a new treatment option for people with myasthenia gravis that doesn't respond to standard therapies.
What could go wrong: This is an extremely early study with only 2 participants, so results may not apply to others. The drug also has risks like immune reactions and side effects from targeting the immune system.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS (MG)

More trials for these conditions

Other studies related to the condition(s) this trial covers.